US mulls more genetic testing oversight for FDA
This article was originally published in Clinica
US health officials and their advisors are looking at setting up a regulatory system for genetic testing. It would mean that once a product passes a certain experimental threshold, it would automatically be required to undergo a form of premarket review by the US FDA.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.